Get the Stockscreener App
1.33
0.76%
0.01
Werewolf Therapeutics Inc stock is traded at $1.33, with a volume of 239.69K.
It is up +0.76% in the last 24 hours and up +1.53% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
See More
Previous Close:
$1.32
Open:
$1.31
24h Volume:
239.69K
Relative Volume:
0.49
Market Cap:
$59.68M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-1.2788
EPS:
-1.04
Net Cash Flow:
$-33.38M
1W Performance:
+13.68%
1M Performance:
+1.53%
6M Performance:
-10.74%
1Y Performance:
-34.16%
1-Day Range:
$1.25
$1.40
1-Week Range:
$1.15
$1.40
52-Week Range:
$0.595
$4.18
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.33 | 59.23M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Custom watchlist performance reports with Werewolf Therapeutics Inc.2025 Market Outlook & Daily Stock Momentum Reports - Newser
Using data filters to optimize entry into Werewolf Therapeutics Inc.Market Trend Review & Community Verified Watchlist Alerts - Newser
Full technical analysis of Werewolf Therapeutics Inc. stockEarnings Overview Summary & AI Forecast Swing Trade Picks - Newser
When is the best time to exit Werewolf Therapeutics Inc.2025 Year in Review & Proven Capital Preservation Tips - Newser
Why Werewolf Therapeutics Inc. is moving today2025 Market Overview & Fast Moving Market Watchlists - Newser
Smart tools for monitoring Werewolf Therapeutics Inc.’s price actionGap Up & Community Consensus Stock Picks - Newser
Real time alert setup for Werewolf Therapeutics Inc. performanceBond Market & Capital Efficiency Focused Ideas - Newser
What recovery options are there for Werewolf Therapeutics Inc.2025 Earnings Surprises & Stepwise Trade Signal Implementation - Newser
Is Werewolf Therapeutics Inc. backed by strong institutional buyingWeekly Earnings Recap & Smart Investment Allocation Insights - sundaytimes.kr
Using data models to predict Werewolf Therapeutics Inc. stock movementJobs Report & Technical Pattern Based Buy Signals - Newser
Is Werewolf Therapeutics Inc. meeting your algorithmic filter criteriaTrend Reversal & Weekly Setup with High ROI Potential - Newser
Werewolf Therapeutics reports Q2 EPS (40c), consensus (37c) - MSN
Werewolf Therapeutics Reports Q2 2025 Financial Results - MSN
Werewolf Therapeutics Inc. stock momentum explained2025 Key Lessons & Weekly Breakout Stock Alerts - Newser
Published on: 2025-08-15 16:22:03 - Newser
Can swing trading help recover from Werewolf Therapeutics Inc. lossesQuarterly Trade Report & AI Forecasted Entry and Exit Points - Newser
Werewolf Therapeutics Reports Q2 EPS of -$0.40, Beating Estimates - AInvest
Werewolf Therapeutics Faces Regulatory and Financial Challenges Amid FDA Disruptions - TipRanks
Is Werewolf Therapeutics Inc. in a bullish channel2025 Dividend Review & Free Risk Controlled Daily Trade Plans - sundaytimes.kr
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Reports Q2 2025 Revenue of $0, Declines 100% YoY. - AInvest
Werewolf Reports No Revenue in Fiscal Q2 - The Motley Fool
Werewolf Therapeutics, Inc. SEC 10-Q Report - TradingView
Werewolf Therapeutics: Capitalizing on Immuno-Oncology Innovation with a Strategic Path to Commercialization - AInvest
Cancer Drug Developer Werewolf Sets Q4 Melanoma Trial Readout, Unveils New Prostate Cancer Program - Stock Titan
Using economic indicators to assess Werewolf Therapeutics Inc. potential2025 Bull vs Bear & Precise Swing Trade Entry Alerts - Newser
Relative strength of Werewolf Therapeutics Inc. in sector analysisJuly 2025 Big Picture & Safe Entry Momentum Tips - Newser
Key metrics from Werewolf Therapeutics Inc.’s quarterly dataQuarterly Trade Summary & Trade Opportunity Analysis Reports - Newser
Published on: 2025-08-13 22:40:57 - 선데이타임즈
Understanding Werewolf Therapeutics Inc.’s price movementMarket Rally & Free Community Supported Trade Ideas - Newser
Analyzing Werewolf Therapeutics Inc. with risk reward ratio chartsAI-Based Signal Detection for Active Traders - Newser
Visual analytics tools that track Werewolf Therapeutics Inc. performanceQuarterly Earnings Summary & Community Supported Trade Ideas - Newser
Analyzing Werewolf Therapeutics Inc. with multi timeframe chartsStrong Buy Opportunity with Volume Support - Newser
How institutional ownership impacts Werewolf Therapeutics Inc. stockLong Term Stock Planner with Safety Checks - Newser
Short interest data insights for Werewolf Therapeutics Inc.Free Smart Allocation Stock Pick Insights - Newser
Strategies to average down on Werewolf Therapeutics Inc.Free Swing Trade Entry With Volume Triggers - Newser
Using Python tools to backtest Werewolf Therapeutics Inc. strategiesLong-Term Allocation Strategy Summary Breakdown - Newser
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):